Persistent Genital Arousal Disorder in Men
PGAD / restless genital syndrome (genito-pelvic dysesthesia)
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No FDA-approved treatment; management targets contributing causes
Reference only. Not medical advice.
What can go wrong
PGAD is genuinely distressing and has been associated with significant psychological burden; it is frequently misunderstood or dismissed. Because causes are heterogeneous and evidence is thin, evaluation should look for treatable contributors (neuroimaging where sacral pathology is suspected, medication review, pelvic-floor assessment) rather than assuming a single fix. No therapy is approved, and management is individualized and often imperfect.
This is something to take to a clinician. The Atlas can tell you what is known about persistent genital arousal disorder in men in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Persistent genital arousal disorder (PGAD), also called restless genital syndrome (ReGS) or genito-pelvic dysesthesia, is a distressing, unwanted, persistent sensation of genital arousal occurring without sexual desire or stimulation, often unrelieved, or only briefly relieved, by orgasm, and lasting hours to days. It is most described in women but is reported in men. Causes are unknown and likely heterogeneous: neurological (including sacral nerve-root irritation from Tarlov cysts), vascular, pharmacological (including medication changes such as SSRI cessation), and pelvic-floor contributions, with overlap to restless legs syndrome.
Arousal that arrives uninvited, persists, and orgasm won't switch off.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
PGAD is thought to reflect aberrant sensory signaling in the genital sensory pathways. Proposed contributors include compression or irritation of sacral nerve roots (Tarlov cysts and cauda-equina-level lesions), small-fiber or pudendal neuropathy, pelvic-floor muscle dysfunction, vascular factors, and medication effects, notably symptom onset around starting or stopping serotonergic drugs. The shared phenomenology with restless legs syndrome has prompted the 'restless genital' framing.
Safety in detail
Suspected sacral or neurologic causes require specialist evaluation and imaging under physician direction. Do not alter serotonergic medications without clinical guidance, as both starting and stopping them have been linked to symptom changes.
What people get wrong
Often saidPGAD only affects women
ActuallyIt is more commonly described in women but is documented in men, where it is even more under-recognized.
Often saidUnwanted persistent arousal is just a high sex drive
ActuallyIt occurs without desire, is unpleasant and distressing, and is poorly relieved by orgasm, the opposite of welcome arousal.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Also called
- Restless genital syndrome; genito-pelvic dysesthesia
- Core feature
- Unwanted arousal without desire, poorly relieved by orgasm
- Possible cause
- Sacral nerve-root irritation (e.g., Tarlov cysts)
- Overlap
- Restless legs syndrome; pelvic-floor dysfunction
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Persistent Genital Arousal Disorder in Men. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Case reports of PGAD with Tarlov cystsvarious
Describe sacral nerve-root cysts as a potential structural contributor in selected patients
Reports linking PGAD to SSRI changesvarious
Note onset of symptoms around paroxetine cessation and other serotonergic shifts in some cases